One of the intriguing themes that emerged recently at ASCO from several cancer immunotherapy trials centred around whether any elicited immune responses actually correlated with outcomes and if so, why and how?
Gems from the ASCO17 poster hall
It sounds easy in practice, yet in reality the topic has been quite a controversial one that has been hotly debated for a while.
With a wealth of new cancer immunotherapy trials now undwerway and initial results trickling out, how do we start to make sense of the information and what do we learn that might be useful going forward for future trials and the field as a whole?
With the help of a renowned cancer immunologist, we explored this concept in more detail to determine what can be gleaned from the data available.
Today, we look at part one of our latest mini-series, with the second part to follow later this week.
Subscribers can log-in to read our latest insights or you can purchase access to BSB Premium Content.
Yesterday, we had a sarcoma expert in the spotlight looking at the new developments from the American Society of Clinical Oncology (ASCO).
In part two of our sarcoma mini-series, we have another interview for our readers, this time from the perspective of the CEO, Dr Carlos Paya. They had some interesting data in Chicago so what was their reaction to it and where are they going next?
To learn more subscribers can log-in or you can purchase access to BSB Premium Content.
Sarcomas are a heterogeneous type of cancer that develop from certain tissues like bone or soft tissues such fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues.
Over the last two years, much has happened in this space so it’s an excellent time to revisit the niche and learn more about what experts think of the latest data that is emerging here.
We put a sarcoma expert in the spotlight and learned what their perspectives are on some of the emerging data in this niche as well as which ones offer hints of promise.
To learn more about the insights in STS, subscribers can log-in or you can purchase access to BSB Premium Content.
As we all wearily trawl through the huge mountain of data for ASCO 2017, what stands out – and more importantly – what matters and why?
Before we get into our in-depth coverage based on the tumour type, target and modality landscapes, I wanted to take a moment to highlight five key abstracts that stood out for me as worthy of checking out in more detail once we get to Chicago.
Interestingly, only one of them is from big Pharma!
At least one had some negatives associated with it as we’re not all happy clappy everything is great enthusiasts here at BSB. We do try to be fair minded and objective as possible about data.
So what’s in store and why do these five matter?
To learn about our insights, subscribers can login to read more
After several years in the wastelands of cancer research due to lack of significant results and only one product on the market, therapeutic cancer vaccines now look to be back in fashion and are seeing a revival with their inclusion in clinical trials.
One of the reasons behind the resurgence of interest is the advent of checkpoints, and the potential of vaccines in the immuno-oncology space to boost or enhance the immune response.
Their use could not only increase the response to checkpoint inhibitors in people who might otherwise not respond, but in those who obtain some initial response such as a partial response, they could also potentially help achieve a more durable long-term response.
As we continue to ride the wave of cancer immunotherapy on BSB, the cancer vaccine field is suddenly an exciting area to watch.
I’ve long been known as a cancer vaccine sceptic, although recently several approaches in this niche have begun to look rather promising indeed. Here, we highlight and discuss one such company in the field, including an interview with the CEO.
Subscribers can login to read more insights…
Over the last year or two, we have covered a number of different pathways that are involved with the immune system including CD19 and 20, CTLA–4, PD–1 and PD-L1, IDO1, CD40, OX40, TIGIT, ICOS and others.
Today, it’s the turn of an oncoprotein called NY-ESO–1 that has been garnering quite a bit of attention of late and will also be highly relevant to some upcoming posts and thought leader interviews we have scheduled here on Biotech Strategy Blog. It’s always a good idea to cover the basics first, before exploring the more advanced concepts.
To learn more about these sentiments and insights, subscribers can log-in or you can purchase access to BSB Premium Content below…